S-1: Processa Pharmaceuticals Seeks Up to $7.5 Million in Public Offering to Advance Cancer Drug Pipeline

Processa Pharmaceuticals is launching a public offering of common stock and pre-funded warrants to raise capital for its NGC-Cap Phase 2 clinical trial and general corporate purposes.

Summary

• Processa Pharmaceuticals, a clinical-stage biopharmaceutical company, has filed a registration statement for a public offering.
• The offering includes shares of common stock and pre-funded warrants, with the goal of raising up to $7.5 million.
• The company intends to use the net proceeds to fund the Phase 2 clinical trial of its NGC-Cap drug, as well as for working capital and general corporate purposes.
• The offering will terminate on a specified date in 2024, but the company may decide to terminate it earlier.
• The company's common stock is listed on The Nasdaq Capital Market under the symbol PCSA.
• The company is a smaller reporting company and has elected to comply with certain reduced public company reporting requirements.
• The company believes that the net proceeds from this offering, together with its cash on hand, will satisfy its capital needs until a certain date under its current business plan, but will need to raise additional capital in 2025.
• The offering is being made on a best-efforts basis, and there is no guarantee that the company will sell all of the securities offered.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is actively pursuing funding for its clinical trials and has achieved some milestones, it also faces financial challenges and uncertainties regarding the success of the offering and future funding needs.

Positives

• The company has a clear plan for the use of proceeds, focusing on advancing its NGC-Cap clinical trial.
• The company's regulatory science approach may increase the probability of FDA approval for its drugs.
• The company's NGC drugs have the potential to improve the safety and efficacy profiles of existing cancer treatments.
• The company has initiated a Phase 2 trial of NGC-Cap and dosed the first patient on October 2, 2024.
• The company has received IND clearance from the FDA for the treatment of advanced and metastatic breast cancer on July 24, 2024.

Negatives

• The offering is being made on a best-efforts basis, and there is no guarantee that the company will raise the full $7.5 million.
• The company has a history of operating losses and expects to continue to incur substantial costs for the foreseeable future.
• The company will need to raise additional capital in 2025 to fund its operations and continue its planned development of its NGC drugs.
• The company's financial situation creates doubt whether it will continue as a going concern.
• The company may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us.

Risks

• The company needs to raise additional capital to fund its operations.
• The company has incurred recurring losses since inception and had an accumulated deficit of approximately $84.5 million as of September 30, 2024.
• The company's estimates of the amount of cash necessary to fund its activities may prove to be wrong.
• The company cannot be certain that additional funding will be available on acceptable terms, or at all.
• The company may be required to significantly delay, scale back or discontinue the development of its product candidates if it is unable to raise additional capital when required or on acceptable terms.
• The company's financial situation creates doubt whether it will continue as a going concern.
• The company may not raise the amount of capital it believes is required for its business plans, including its near-term business plans.
• If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about the company's business, its stock price and trading volume could decline.
• Future sales of the company's common stock, warrants, or securities convertible into its common stock may depress its stock price.
• The company does not anticipate paying any cash dividends on its common stock in the foreseeable future.
• Significant holders or beneficial holders of the company's common stock may not be permitted to exercise Pre-Funded Warrants that they hold.

Future Outlook

The company believes that the net proceeds from this offering, together with its cash on hand, will satisfy its capital needs until a certain date under its current business plan. In 2025, the company will need to raise additional capital to fund its operations and continue its planned development of its NGC drugs.

Industry Context

The company operates in the biopharmaceutical industry, specifically focusing on oncology drug development. The company's strategy aligns with the FDA's Project Optimus Oncology initiative, which aims to optimize dosage regimens for oncology drugs.

Comparison to Industry Standards

• The company compares the efficacy response rate and progression-free survival of NGC-Cap in its Phase 1B trial to the overall response rate and time to progression reported in the capecitabine product label.
• The company notes that in the capecitabine product label, 301 metastatic colorectal cancer patients treated with monotherapy capecitabine had an overall response rate of approximately 21% and the time to progression of approximately 4.5 months.
• The company also compares the hand-foot syndrome rate in its Phase 1B trial to the expected rate based upon published data for capecitabine.

Stakeholder Impact

• The offering could impact shareholders through dilution.
• The success of the clinical trials could impact patients by providing new treatment options.
• The company's financial stability could impact employees.

Next Steps

• Continue the Phase 2 clinical trial of NGC-Cap.
• Evaluate options to monetize non-core drug assets.
• Expand the preclinical analysis of NGC-Iri, including additional efficacy and toxicity studies.
• Evaluate manufacturing options for PCS11T (NGC-Iri).
• Conduct chemistry, manufacturing and control (CMC) activities and pre-IND enabling studies for NGC-Iri.
• Meet with the FDA to discuss potential trial designs for NGC-Gem.
• Continue discussions with Yuhan to amend the existing license agreement for PCS12852.

Key Dates

Keywords

public offering, Processa Pharmaceuticals, NGC-Cap, pre-funded warrants, clinical trial, oncology, biopharmaceutical, FDA, capital raise, chemotherapy